

# PATENT COOPERATION TREATY

## PCT

### NOTE OF INFORMAL COMMUNICATION WITH THE APPLICANT

(PCT Rule 66.6)

International application No. <b>PCT/US03/36247</b>	Applicant's or agent's file reference <b>GENO200.3.</b>	Date of informal communication (day/month/year)
Applicant <b>EVOLUTIONARY GENETICS LLC</b>		

<u>Communication</u>  <input checked="" type="checkbox"/> by telephone  <input type="checkbox"/> personal	<u>Participants</u>  <input checked="" type="checkbox"/> Applicant: <b>EVOLUTIONARY GENETICS LLC</b> <input checked="" type="checkbox"/> Agent: <b>Ms Yoerg</b> <input checked="" type="checkbox"/> Examiner(s): <b>Sally Sakelaris</b>	<input checked="" type="checkbox"/> Identity checked  <input checked="" type="checkbox"/> authorization checked  <input type="checkbox"/> personally known
---	---	--


Summary of communication:

It was agreed upon that the 408(Written Opinion) would be waived and a 409 (International Preliminary Examination Report) would be prepared and mailed. Ms. Yoerg acknowledged that waiving the 408 resulted in the loss of a right to respond to the 408.

☐ An extension of time limit is granted (Form PCT/IPEA/427).

☒ A copy of this note is being sent to the applicant with Form PCT/IPEA/429.

PCT/IPEA/424.

Name and mailing address of the IPEA/US Mail Stop PCT, Attn: IPEA/ US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (703) 305-3230	Authorized officer  Sally Sakelaris Telephone No. 571-272-0500
--	---

8. The method of claim 6, wherein said substantial reduction in sensitivity to Gram-negative bacterial infection is determined by an indicator selected from the group consisting of:

- (a) elimination or substantial reduction in host systemic inflammatory response to LPS in a human, non-human primate, or suitable animal model; and
- (b) elimination or reduced severity of central nervous system dysfunction, adult respiratory distress syndrome, liver failure, acute renal failure, and/or disseminated intravascular coagulation in a human, non-human primate, or suitable animal model.

10

9. A method for treating sepsis, severe sepsis or septic shock in a primate, comprising:

administering to a primate in need thereof an effective dose of a therapeutic agent identified according to the method of claim 6.

15

10. A method for treating asthma in a primate, comprising:

administering to a primate in need thereof an effective dose of a therapeutic agent identified according to the method of claim 6.

20

11. A therapeutic agent identified according to the method of claim 6.

12. A composition comprising a polynucleotide selected from the group consisting of chimpanzee *TLR4* polynucleotide (SEQ. ID. NO. \_\_\_\_), gorilla *TLR4* polynucleotide (SEQ. ID. NO. \_\_\_\_), gibbon *TLR4* polynucleotide (SEQ. ID. NO. \_\_\_\_), rhesus monkey *TLR4* polynucleotide (SEQ. ID. NO. \_\_\_\_), capuchin *TLR4* polynucleotide (SEQ. ID. NO. \_\_\_\_), squirrel monkey *TLR4* polynucleotide (SEQ. ID. NO. \_\_\_\_), and baboon *TLR4* polynucleotide (SEQ. ID. NO. \_\_\_\_).

25

13. A composition comprising a polypeptide selected from the group consisting of chimpanzee *TLR4* polypeptide (SEQ. ID. NO. \_\_\_\_), gorilla *TLR4* polypeptide (SEQ. ID. NO. \_\_\_\_), gibbon *TLR4* polypeptide (SEQ. ID. NO. \_\_\_\_), rhesus monkey *TLR4* polypeptide (SEQ. ID. NO. \_\_\_\_), capuchin *TLR4* polypeptide (SEQ. ID. NO. \_\_\_\_), squirrel monkey *TLR4* polypeptide (SEQ. ID. NO. \_\_\_\_), and baboon *TLR4* polypeptide (SEQ. ID. NO. \_\_\_\_).

30